MWNA
BMRN icon

Marshall Wace North America’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marshall Wace North America’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$11.8M Buy
152,108
+118,275
+350% +$9.33M 0.05% 320
2021
Q2 		$2.82M Buy
+33,833
New +$2.68M 0.01% 711
2021
Q1 		– Sell
-404,687
Closed -$35.5M – 1513
2020
Q4 		$35.5M Sell
404,687
-588,168
-59% -$46.6M 0.16% 157
2020
Q3 		$75.5M Buy
992,855
+521,365
+111% +$52.7M 0.48% 44
2020
Q2 		$58.2M Sell
471,490
-256,268
-35% -$25.5M 0.38% 66
2020
Q1 		$61.5M Buy
727,758
+471,483
+184% +$40.6M 0.47% 60
2019
Q4 		$21.7M Buy
256,275
+21,908
+9% +$1.65M 0.1% 192
2019
Q3 		$15.8M Sell
234,367
-305,838
-57% -$23.6M 0.09% 197
2019
Q2 		$46.3M Buy
540,205
+135,130
+33% +$11.6M 0.29% 93
2019
Q1 		$36M Sell
405,075
-314,680
-44% -$29.2M 0.25% 98
2018
Q4 		$61.3M Buy
719,755
+164,546
+30% +$15.7M 0.59% 46
2018
Q3 		$53.8M Buy
555,209
+257,073
+86% +$25.7M 0.37% 73
2018
Q2 		$28.1M Buy
+298,136
New +$26.1M 0.16% 153
2018
Q1 		– Sell
-437,830
Closed -$39M – 1436
2017
Q4 		$39M Buy
437,830
+413,173
+1,676% +$35.9M 0.22% 105
2017
Q3 		$2.29M Sell
24,657
-227,908
-90% -$20.1M 0.01% 763
2017
Q2 		$23M Sell
252,565
-172,618
-41% -$15.7M 0.17% 156
2017
Q1 		$37.4M Buy
+425,183
New +$37.8M 0.3% 98

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Marshall Wace North America's BMRN Position: Q3 2021 in Review

Marshall Wace North America increased its BioMarin Pharmaceuticals (BMRN) stake by 350% in Q3 2021, buying an estimated $9.33M and bringing the position to 152,108 shares worth $11.8M. The position accounts for 0.05% of the portfolio, ranked #320.

Marshall Wace North America first reported a position in BMRN in Q1 2017 and has held it in 17 quarters since. The position peaked at $75.5M in Q3 2020. 513 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Marshall Wace North America held 152,108 shares of BioMarin Pharmaceuticals worth $11.8M as of Q3 2021.
  • Marshall Wace North America bought 118,275 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $9.33M.
  • BioMarin Pharmaceuticals made up 0.05% of Marshall Wace North America's portfolio in Q3 2021, its #320 holding.
  • Marshall Wace North America first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
  • Marshall Wace North America's BioMarin Pharmaceuticals position peaked at $75.5M in Q3 2020.
  • 513 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.